ATE265855T1 - 4-(2-(n-(-2-carboxamidoindole)aminiethyl)- benzensulfonamide oder sulfonylharnstoffe als pdgf antagoniste - Google Patents

4-(2-(n-(-2-carboxamidoindole)aminiethyl)- benzensulfonamide oder sulfonylharnstoffe als pdgf antagoniste

Info

Publication number
ATE265855T1
ATE265855T1 AT96916719T AT96916719T ATE265855T1 AT E265855 T1 ATE265855 T1 AT E265855T1 AT 96916719 T AT96916719 T AT 96916719T AT 96916719 T AT96916719 T AT 96916719T AT E265855 T1 ATE265855 T1 AT E265855T1
Authority
AT
Austria
Prior art keywords
carboxamidoindole
benzenesulfonamides
aminiethyl
intimal hyperplasia
methods
Prior art date
Application number
AT96916719T
Other languages
English (en)
Inventor
Charles E Hart
Mark W Orme
Kristen M Moynihan
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of ATE265855T1 publication Critical patent/ATE265855T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96916719T 1995-06-30 1996-05-29 4-(2-(n-(-2-carboxamidoindole)aminiethyl)- benzensulfonamide oder sulfonylharnstoffe als pdgf antagoniste ATE265855T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74395P 1995-06-30 1995-06-30
PCT/US1996/007881 WO1997002036A1 (en) 1995-06-30 1996-05-29 4-(2-(n-2-carboxamidoindole)aminoethyl)-benzenesulfonamides or sulfonylureas as pdgf antagonists

Publications (1)

Publication Number Publication Date
ATE265855T1 true ATE265855T1 (de) 2004-05-15

Family

ID=21692834

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96916719T ATE265855T1 (de) 1995-06-30 1996-05-29 4-(2-(n-(-2-carboxamidoindole)aminiethyl)- benzensulfonamide oder sulfonylharnstoffe als pdgf antagoniste

Country Status (9)

Country Link
US (1) US5731326A (de)
EP (1) EP0835115B1 (de)
JP (1) JP3195363B2 (de)
AT (1) ATE265855T1 (de)
AU (1) AU5938696A (de)
DE (1) DE69632402T2 (de)
DK (1) DK0835115T3 (de)
ES (1) ES2217313T3 (de)
WO (1) WO1997002036A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US8236048B2 (en) * 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US7300662B2 (en) 2000-05-12 2007-11-27 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US20040243097A1 (en) * 2000-05-12 2004-12-02 Robert Falotico Antiproliferative drug and delivery device
US20020051730A1 (en) * 2000-09-29 2002-05-02 Stanko Bodnar Coated medical devices and sterilization thereof
CA2424029C (en) 2000-09-29 2008-01-29 Cordis Corporation Coated medical devices
US7261735B2 (en) * 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
US20020111590A1 (en) * 2000-09-29 2002-08-15 Davila Luis A. Medical devices, drug coatings and methods for maintaining the drug coatings thereon
MXPA03012031A (es) * 2001-06-21 2005-07-01 Univ Yale El monoxido de carbono mejoraresultados en transplantes de tejido y organo y suprime apoptosis.
US7195640B2 (en) * 2001-09-25 2007-03-27 Cordis Corporation Coated medical devices for the treatment of vulnerable plaque
US20030065345A1 (en) * 2001-09-28 2003-04-03 Kevin Weadock Anastomosis devices and methods for treating anastomotic sites
US20030065377A1 (en) * 2001-09-28 2003-04-03 Davila Luis A. Coated medical devices
US7108701B2 (en) * 2001-09-28 2006-09-19 Ethicon, Inc. Drug releasing anastomosis devices and methods for treating anastomotic sites
BRPI0307673A2 (pt) * 2002-02-13 2016-11-08 Beth Israel Hospital métodos de tratar doença vascular.
RS91004A (sr) * 2002-04-15 2007-02-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education, Postupci za lečenje ileusa
WO2003088748A1 (en) 2002-04-15 2003-10-30 Beth Israel Deaconess Medical Center Use of heme oxygenase-1 and products of heme degradation
EP1499328B1 (de) * 2002-04-15 2015-09-16 University of Pittsburgh - Of the Commonwealth System of Higher Education Verfahren zur behandlung von nekrotisierender enterocolitis
JP4549847B2 (ja) 2002-05-17 2010-09-22 イエール ユニバーシティ 肝炎の治療方法
UA87438C2 (ru) * 2002-06-05 2009-07-27 Йельский Университет Способы лечения или профилактики рака, способ проведения хирургической операции по удалению рака и применения монооксида углерода
PL377733A1 (pl) * 2002-11-07 2006-02-06 University Of Pittsburgh Of The Commonwealth System Of Higher Education Leczenie wstrząsu krwotocznego
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
JP2009235057A (ja) * 2007-10-31 2009-10-15 Santen Pharmaceut Co Ltd 血管新生阻害活性を有する新規インドール誘導体
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670700B2 (de) * 1966-05-14 1978-06-22 Hoechst Ag, 6000 Frankfurt Benzolsulfonylharnstoffe, Verfahren zu ihrer Herstellung und deren Verwendung
US5280016A (en) * 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
CA2094858C (en) * 1992-04-28 2004-06-15 Robert D. Mitchell Method of treating hyperproliferative vascular disease
JP3465247B2 (ja) * 1992-12-28 2003-11-10 アベンティス ファーマ株式会社 動脈硬化症の予防および治療剤
US5976534A (en) * 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin

Also Published As

Publication number Publication date
WO1997002036A1 (en) 1997-01-23
DE69632402T2 (de) 2005-05-19
AU5938696A (en) 1997-02-05
ES2217313T3 (es) 2004-11-01
DE69632402D1 (en) 2004-06-09
US5731326A (en) 1998-03-24
JP3195363B2 (ja) 2001-08-06
EP0835115B1 (de) 2004-05-06
EP0835115A1 (de) 1998-04-15
DK0835115T3 (da) 2004-08-02
JP2001502292A (ja) 2001-02-20

Similar Documents

Publication Publication Date Title
ATE265855T1 (de) 4-(2-(n-(-2-carboxamidoindole)aminiethyl)- benzensulfonamide oder sulfonylharnstoffe als pdgf antagoniste
CA2208673A1 (en) Composition for inhibiting intimal hyperplasia using pdgf antagonists and heparin
Sato et al. Tissue factor pathway inhibitor inhibits aortic smooth muscle cell migration induced by tissue factor/factor VIIa complex
FI961270A0 (fi) Takykiniinien antagonisteja ja 3-(5-tetratsolyyli-bentsyyli)amino-piperidiinijohdannaisia
ES2136186T3 (es) Ditiocarbamatos destinados al tratamiento de la aterosclerosis y de otras enfermedades cardiovasculares e inflamatorias.
ATE219084T1 (de) Oxepan-isomere von rapamycin brauchbar als immunosuppressive wirkstoffe
ATE339505T1 (de) Antagoniste von interleukin-15
DK0831807T3 (da) Anvendelse af Brefeldin A og derivater deraf til fremstilling af lægemidler til behandling af hyperplasia og beslægtede lidelser
DE59911005D1 (de) Aminosäureester von arylsulfonamiden und analoga
ATE165511T1 (de) Behandlung von organtransplantatsabstossung
DE59601122D1 (de) N-(Benzofurazanyl)-Arylsulfonamide und ihre Analoge verwendbar als Endothelin-Rezeptor-Antagonisten
DE69232323D1 (de) Verwendung von Adenosinantagonisten zur Vorbeugung und Behandlung von Pankreatitis und Ulcera
ATE263187T1 (de) Neuartige heparin bindende peptide
ATE253582T1 (de) Prodrogs und analoga von camptothecin und deren verwendung als arzneimittel
DE69413009D1 (de) Verwendung von antikörpern gegen pdgf-rezeptoren zur inhibierung von hyperplasie der intima
DK0680323T3 (da) Synergistisk kombination med antagonistvirkning ved NK1- og Nk2-receptorer.
ATE201207T1 (de) Substituierte imidazo(4,5-b)pyridine und benzimidazole als angiotensin ii antagoniste
IT9048102A0 (it) Derivati oligopeptidici dell'ipoxantina dotati di attivita' immunomodulante e composizioni farmaceutiche che li contengono
ES2045008T3 (es) Procedimiento para la obtencion de preparados en combinacion antidepresivos.
CY1106540T1 (el) Ετεροκυλικα υποκατεστημενες στη θεση 3 πιπεριδινο-2,6-διονες
DE69928539D1 (de) Zielrichtung und verlängerte assoziation von wirkstoffen an die luminale oberfläche der pulmonaren vaskularen endothelzellen
WO1995030438A3 (en) Methods and compositions to enhance endogenous fibrinolytic activity
DE68925990D1 (de) Verwendung von 1,2,4-Trioxanen als Anti-Parasitika und Anthelmintika
KR940024274U (ko) 당구 큐대의 담부 손질 기구
FR2681785B1 (fr) Utilisation de 4-amino-1-(2-pyridyl)piperidines en tant qu'agents anticonvulsivants et antiepileptiques.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0835115

Country of ref document: EP

REN Ceased due to non-payment of the annual fee